The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
Artigos recentes
- EMA Guideline on registry-based studies
- As formações de outubro e novembro , já prontas para avançar, recebem os creditos da OF
- How incidents with medicines are managed in the EU – a ten-year analysis by EMA
- Regulating medical devices from 1 January 2021 for the UK medical devices market
- Últimas vagas para a 6ª Edição da formação sobre Gestão de Reclamações, Devoluções, Falsificados e Recolhas de Mercado
- Making best use of big data for public health: publication of the Big Data Steering Group workplan for 2020-21
- Guidelines 07/2020 on the concepts of controller and processor in the GDPR
- NOVAS DATAS para a formação sobre as BOAS PRÁTICAS DE DISTRIBUIÇÃO DE MEDICAMENTOS E DISPOSITIVOS MÉDICOS